ArticleAmerican journal of translational research2026
Efficacy of calcium sulfate particles combined with allogeneic bone grafting on bone defects after surgery for benign bone tumors of the extremities.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBenign extremity bone tumors significantly impact patients' quality of life. While autologous bone grafting increases surgical trauma and donor-site complications, allogeneic bone grafting carries risks of infection and rejection.
objectiveTo evaluate the efficacy of calcium sulfate (CS) particles combined with allogeneic bone grafting for bone defects following benign extremity bone tumor surgery.
methodsThis retrospective analysis included 121 patients treated at Honghui Hospital (Jan 2018-Dec 2020). The control group (CG, n=60) received CS artificial bone grafts, while the research group (RG, n=61) received CS combined with allogeneic bone grafts. Outcomes included treatment efficacy, drainage volume, soft tissue swelling resolution time, bone healing time, particle absorption time, residual bone defect rate, complications, limb function at 18 months postoperatively, Pain scores (VPS) of the two groups before and after treatment and quality of life at 6, 12, and 18 months postoperatively.
resultsThe RG demonstrated a significantly higher total effective rate compared to the CG. Postoperative drainage volume and soft tissue swelling disappearance time were notably reduced in the RG. Additionally, the RG showed shorter bone healing time and particle complete absorption time, lower residual bone defect rate after artificial bone absorption, and decreased incidence of wound infection and delayed healing. The VAS score of patients in the RG group improved more significantly than that of the CG. Limb function at 18 months and quality of life at 6 and 12 months were significantly better in the RG.
conclusionsCS particles combined with allogeneic bone grafting effectively reduces postoperative bone defects, promotes recovery, and improves quality of life in patients with benign extremity bone tumors, warranting clinical promotion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.